Table 1.
Study group demographics
| Prediction model cohort | Validation cohort | ||
|---|---|---|---|
|
| |||
| CN (@baseline) | MCI (@ 1st 11C-PiB PET imaging) | MCI (@baseline) | |
| N | 46 | 62 | 153 |
| Age, years | 75.87 ± 5.38 | 74.24 ± 7.77 | 74.43 ± 7.52 |
| Sex, % female | 51% | 32% | 35% |
| Education, years | 15.91 ± 2.22 | 16.26 ± 2.77 | 15.47 ± 3.00 |
| ApoE- ε3/ε4 carriers, % | 0% | 42% | 40% |
| ApoE- ε4/ε4 carriers, % | 0% | 11% | 11% |
| MMSE | 29.20 ± 0.92 | 26.98 ± 2.331 | 26.72 ± 1.861 |
| CDR-SB | 0.02 ± 0.10 | 2.24 ± 1.601 | 1.61 ± 0.921,2 |
| ADAS-Cog | 6.00 ± 3.08 | 11.11 ± 5.411 | 11.94 ± 4.531 |
|
| |||
| Composite PiB-SUVR | - | 1.63 ± 0.29 | - |
| % Aβ+ (i.e., Composite PiB-SUVR > 1.478) | - | 66% | - |
|
| |||
| CSF Aβ1-42 | 243.00 ± 22.99 | 162.23 ± 54.071, 3 | 162.29 ± 53.831 |
| % Aβ+ (i.e., CSF Aβ1-42 < 1929) | 0% | 76%3 | 73% |
1
Two sample t-test group difference in comparison to CN at p<10−9 level
2
Two sample t-test group difference in comparison to prediction model MCI cohort at p=0.017 level
3
Based on 34 MCI subjects who had baseline CSF protein assay